Clinical Pharmacokinetics of Isolated Pelvic Perfusion

Surgical Oncology Clinics of North America

Volumn 17, Issue 4, 2008, Pages 773-784

  Belliveau, James F ^a   Wanebo, Harold J ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Landmark Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; MELPHALAN; MITOMYCIN C; OXALIPLATIN;

ADVANCED CANCER; AREA UNDER THE CURVE; CALCULATION; CANCER CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFUSION; DRUG TISSUE LEVEL; FLAME PHOTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOLATED PELVIC PERFUSION CHEMOTHERAPY; MATHEMATICAL ANALYSIS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PELVIS CANCER; REGIONAL PERFUSION; REVIEW; ULTRAVIOLET SPECTROPHOTOMETRY; URINARY EXCRETION;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; MODELS, THEORETICAL; PELVIC NEOPLASMS;

EID: 49649108460     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2008.04.010     Document Type: Review

References (19)

1. Creech O., Krementz E.T., Ryan R.F., et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148 (1958) 616-632
2. Wile A.G., Stemmer E.A., Andrews P.A., et al. Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. J Clin Oncol 3 (1985) 849-852
3. Wile A., and Smolir M. Hyperthermic pelvic isolation-perfusion in the treatment of refractory pelvic cancer. Arch Surg 122 (1987) 1321-1325
4. Turk P.S., Belliveau J.F., Darnowski J.W., et al. Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique. Arch Surg 128 (1993) 533-539
5. Darnowski J.W., Sawyer R.C., Stolfi R.L., et al. Decreased host toxicity in vivo during chronic treatment with 5-fluorouracil. Cancer Chemother Pharmacol 14 (1985) 63-69
6. den Hartigh J., and van Oort W.J. High-pressure liquid chromatographic determination of the antitumor agent mitomycin C in human blood plasma. Anal Chim Acta 127 (1981) 47-53
7. Forastiere A.A., Belliveau J.F., Goren M., et al. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloro-platinum (II) in head and neck cancer patients. Cancer Res 48 (1988) 3869-3874
8. DeConti R.C., Toftness B.R., Lange R.C., et al. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 33 (1973) 1310-1315
9. Pratt C.B., Hayes A., Green A.A., et al. Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study. Cancer Treat Rep 65 (1981) 1021-1026
10. Vermorken J.B., van der Vijgh W.J.F., Klein I., et al. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 68 (1984) 505-513
11. Reich S.D. Clinical pharmacology of mitomycin C. In: Carter S.K., and Crooke S.T. (Eds). Mitomycin C: current status and new developments (1979), Academic Press, New York 171-180
12. den Hartigh J., McVie J.G., van Oort W.J., et al. Pharmacokinetics of mitomycin C in humans. Cancer Res 43 (1983) 5017-5021
13. Fraile R.J., Baker L.H., Buroker T.R., et al. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 40 (1980) 2223-2228
14. Heggie G.D., Sommadossi J.P., Cross D.S., et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47 (1987) 2203-2206
15. LeRoy A.F., Lutz R.L., Dedrick R.L., et al. Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the Beagle Dog: thermodynamic and kinetic behavior of DDP in a biologic milieu. Cancer Treat Rep 63 (1979) 59-71
16. Litterst C.L., LeRoy A.F., and Guarino A.M. Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals. Cancer Treat Rep 63 (1979) 1489-1492
17. Rixe O., Ortuzar W., Alvarez M., et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 52 (1996) 1855-1865
18. Schmoll H.J. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. Semin Oncol 29 Suppl 15 (2002) 34-39
19. Wagner J.G. In fundamentals of clinical pharmacokinetics (1975), Drug Intell, Bethesda (MD) Pubns.: 1975. p. 22-4